Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adaptive Biotechnologies Corp (ADPT) vs Noble Corporation plc (NE) Price & Performance

Adaptive Biotechnologies CorpTrade
Noble Corporation plcTrade

Price performance (Past 24H)

Key statistics

Adaptive Biotechnologies Corp vs Noble Corporation plc — how do they compare? Adaptive Biotechnologies Corp trades at $25.13 (market cap $4.04B), while Noble Corporation plc trades at $44.32 (market cap $7.10B). The key difference: Noble Corporation plc is the larger of the two by market cap, and Noble Corporation plc pays a 4.5% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.

ADPTNE
Market Cap
$4.04B$7.10B
Sector
HealthTechnology
52-Week High
$25.45$54.37
52-Week Low
$12.30$26.61
Enterprise Value
$4.10B$8.53B
Dividend Yield
4.5%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adaptive Biotechnologies Corp

ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.

Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.

Noble Corporation plc

Noble Corporation (NE) trades at $44.48, up 2.14% today, with a bullish technical signal driven by moving averages. The stock shows mixed earnings performance, with a Q1 2026 beat but a Q2 2026 miss, while revenue and net income have declined year-over-year. Recent news highlights multiple law firm investigations into the company, adding uncertainty. The consensus price target is $46.00, slightly above the current price, with analysts divided between Buy (31%) and Hold (43%) ratings.

The outlook is cautious due to earnings volatility and legal scrutiny, though positive cash flow and a solid backlog of $6.8 billion provide some stability. Key risks include operational suspensions and investor litigation, while potential upside hinges on execution improvements and contract wins. The stock's valuation appears stretched with a P/E of 47.32, demanding strong future growth to justify current levels.

Returns comparison

Trailing returns across standard periods

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Read more on ADPT

About Noble Corporation plc

Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.

Read more on NE